cyrilzakka/clinical-trials huggingface dataset:
PET/MRI Artificial Intelligence Reconstruction Algorithm AIR Recon DL Image Quality Evaluation and Clinical Study

PET/MRI artificial intelligence reconstruction algorithm AIR Recon DL image quality evaluation and clinical study

This is a diagnostic pilot study in which 50 patients with disorders of consciousness, Parkinson's syndrome and 15 prostate cancer patients were recruited to undergo PET/MRI imaging to evaluate the impact of AIR Recon DL on scanning and imaging time in different diseases and imaging sites, to determine its efficiency in clinical applications and to analyse its potential advantages in the diagnosis of specific diseases.

Eligibility Criteria:
Inclusion Criteria:

* 1. Adults between the ages of 18 and 75 who are autonomous; 2. persons with good compliance; 3. those who are mentally alert and able to move around on their own; 4. Those who agree to participate in this clinical trial and sign the informed consent form.

Exclusion Criteria:

* 1. Persons who do not have full capacity for civil behaviour; 2. Women during pregnancy and breastfeeding; 3. other implants, prostheses, foreign bodies and patches with electronic implants such as pacemakers, insulin pumps and cochlear implants that are not suitable for MRI; 4. patients with claustrophobia; 5. those who, in the opinion of the investigator, are not suitable for participation in this clinical trial.
Study of Physician Awareness of and Communication About Patient Readmissions to the Hospital

Patients admitted to inpatient medicine services often require early hospital readmission, and often they are readmitted to different physician or team, potentially without the knowledge of the prior physician or team. Thus, physicians may lose the opportunity to share valuable information about readmitted patients, which may be detrimental to continuity of care and patient safety. The purpose of this study is to determine baseline awareness and communication rates among physicians regarding readmissions, and then measure the effect of automatic notification on these rates.


Eligibility Criteria:
Inclusion Criteria:

* All patients admitted to the general medicine service at two academic medical centers, and unexpectedly readmitted within 14 days.

Exclusion Criteria:

* Patients readmitted to the same physician(s), or those whose readmission was planned
Glyceryl Trinitrate Versus Lidocaine Cream for IUD Insertion

The intrauterine device (IUD) is a long-acting, highly effective, reversible contraceptive method that may be underutilized due to fear of pain during insertion. Although providers frequently prescribe non-steroidal anti-inflammatory drugs (NSAIDs) for IUD insertion, there is no evidence for any pain reduction. Women can experience high levels of pain when the IUD is placed inside the uterus, and fear of this pain could be a reason that women decide not to use this method.


Eligibility Criteria:
Inclusion criteria:

1. Women not taken analgesics or anxiolytics in the 24 hours prior insertion
2. Women not taken misoprostol prior to IUD insertion
3. No contraindication to or history of allergic reaction to lidocaine or NO donors.
4. Women who will accept to participate in the study

Exclusion criteria:

1. Lidocaine allergy
2. History of migraine or chronic headache
3. Any contraindication to IUD placement
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

OBJECTIVES:

I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.

PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution.

The first group receives oral mexiletine 3 times a day for 6 weeks. The dose is increased after the first week if there are no side effects.

The second group receives a placebo. Patients cross to the alternate treatment after a 1-week washout.

Eligibility Criteria:
Patients with painful diabetic neuropathy
Comparison of a Telehealth Versus In-person Intervention for Binge Eating

Adults and adolescents will be asked to participate in a 10-week intervention to better understand their emotions and improve their relationship with food.

Adults and adolescents will be asked to participate in a 10-week eating intervention to better understand and manage their emotions and improve their relationship with food. Participants will fill out questionnaires related to their engagement in body avoidance behaviors and disordered eating, and assess their self-reported levels of impulsivity, food insecurity, mindfulness skills, emotion regulation skills, and distress tolerance skills. Participants will also be asked questions to assess the feasibility and acceptability of the telehealth format.

Eligibility Criteria:
Inclusion Criteria for Adolescent Group:

* Adolescent in high school (ages \~13-18)
* Participant and their caregiver must be able to understand and speak English
* Has access to a computer device or tablet with a microphone and web camera
* Has access to a reliable internet connection and a private, quiet place to complete sessions
* Willing or able to secure transportation to the Texas A\&M University campus if selected for the in-person group
* Engages in loss-of-control eating AND eating within a 2-hour period what most people would consider an unusually large amount of food given the circumstances

Exclusion Criteria for Adolescent Group:

* Active suicidal ideation within the past 2 weeks
* Has been diagnosed with an intellectual disability
* Active psychosis or experiencing psychosis symptoms
* Caregiver is not able to participate

Inclusion for Adult Group:

* Age 18+
* Speaks and understands English
* Has access to a computer device or tablet with a microphone and web camera
* Has access to a reliable internet connection and a private, quiet place to complete sessions
* Willing or able to secure transportation to the Texas A\&M University campus if selected for the in-person group
* Engages in loss-of-control eating AND eating within a 2-hour period what most people would consider an unusually large amount of food given the circumstances

Exclusion Criteria for Adult Group:

* Active suicidal ideation within the past 2 weeks
* Has been diagnosed with an intellectual disability
* Active psychosis or experiencing psychosis symptoms
Hydration and Rate of Cesarean Delivery Among Nulliparous

The hypothesis of the present study is the hydration of nulliparous women with 250ml/hour vs. 125ml/hrs would decrease the rate of primary cesarean section.

For this non-blinded randomized clinical trial (RCT) we will recruit approximately 670 women which meet the inclusion criteria across three sites (Eastern Virginia Medical School (EVMS), University of Arkansas for Medical Sciences (UAMS) and Obstetrix Medical Group, in California). When the patient is being scheduled for induction by her physician or when she presents to L\&D for induction or in labor, but her cervical dilation on admission is less than 4 cm, the participants will be consented, and then randomized into a study intervention group. Both groups will receive maintenance IV hydration with Lactated Ringer's (LR) solution: Group I will receive LR at 125 ml/hr and group II will receive LR at 250ml/hr. Other than the rate of maintenance IV infusion, the two groups will receive routine intrapartum care.

Eligibility Criteria:
Inclusion Criteria:• Non-anomalous singleton

* Nulliparous (no prior delivery after 20 weeks)
* Presenting at ≥37 weeks of gestation
* Presenting for anticipated induction of labor or spontaneous labor (regular contractions for more than 2 hours), but cervical dilation less than 4 cm
* Rupture of membranes
* Expected to deliver at one of the participating hospitals

Exclusion Criteria:• Not in the inclusion criteria

* Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis, scleroderma)
* Diabetes mellitus-gestational or pre-gestational
* Enrollment in another randomized clinical trial
* Hematologic disorders (coagulation defects, sickle cell disease, thrombocytopenia, thrombophilia)
* Hypertension (chronic or pregnancy induced) before randomization
* HIV (human immunodeficiency virus)
* Placenta previa / 3rd trimester bleeding
* Renal insufficiency (serum creatinine \> 1.5 mg/dL)
* Restrictive lung disease
* Seizure disorder on medication
* Thyroid disease on medication
* Any contraindications to vaginal delivery (breech, active herpes, schedule cesarean, abnormal fetal heart tracing)
Biomarker for Peritoneal Ultrafiltration Failure

This study will examine the peritoneal tissue, serum and dialysate proteins of peritoneal dialysis (PD) patients with different types of peritoneal solute transport by differential proteomics techniques.

This study will be performed to identify the molecular difference between different types of peritoneal solute transport and explore biomarker for early detection as well as early intervention of peritoneal ultrafiltration failure.

Ultrafiltration failure (UFF) is an important cause of technical failure in PD patients. It may develop over time and is, therefore, especially important in longterm PD. However, the study on UFF is very limited so far, there are still lack of biomarker for early detection and intervention of UFF.

Proteomics uses a rapidly evolving group of technologies to identify, quantify, and characterize a global set of proteins. It is characterized by high-throughput, high specificity and high-sensitivity. Therefore, proteomics has become a major focus of recent medical research.

This study will examine the peritoneal tissue, serum and dialysate proteins of continuous ambulatory peritoneal dialysis (CAPD) patients with different types of peritoneal solute transport by differential proteomics techniques. Correlation analysis will be used for the relationship between clinical data and the differential proteins, as well as verification of the differential proteins in the peritoneal tissue, serum and dialysate of patients with UFF. This study will be performed to identify the molecular difference between different types of peritoneal solute transport and explore biomarker for early detection as well as early intervention of peritoneal ultrafiltration failure.

Eligibility Criteria:
Inclusion Criteria:

* Continuous ambulatory peritoneal dialysis patients whose primary disease is chronic glomerulonephritis, The range of age is 20 to 65 year old.
* serum albumin level ≥ 35 g/L.
* Residual GFR ≥ 2 ml/min/1.73 m2.
* 500 ml/d ≤ urine output ≤ 1000 ml/d.
* Subjects who agree to participate in the study and sign the informed consent.

Exclusion Criteria:

* Patients who are secondary nephropathy.
* Patients with congestive heart failure, angina, myocardial infarction, severe valvular heart disease, malignant hypertension, hypertensive encephalopathy or cerebrovascular accident.
* Patients with chronic liver disease, dyscrasia, psychiatric disorder, alcohol or drug abuse.
Effectiveness of Two Intracanal Irrigation Solutions

The aim of the present clinical trial is to investigate and compare the effect of crayotherapy utilizing two intra-canal final irrigating solutions on postoperative pain.

1. st: Comparison of pain reduction algorism after cryotherapy using the two tested irrigating materials
2. nd. Number and frequency of analgesics taken for pain relief during one week postoperative

Eligibility Criteria:
Inclusion Criteria:

* Case diagnosed as having symptomatic irreversible pulpitis with symptomatic apical periodontitis
* Patients requiring emergency RCT
* Pre-operative pain score 7 on Numerical Rating (NRS) scale
* Middle aged males (25-50)
* Medical profile ASA1
* Willing to sign the consent form
* Willing to answer our call for one week period

Exclusion Criteria:

* Females
* Medical conditions above ASA1
* Multi-rooted teeth
* Patients younger or older than (25-50)
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer

Analysis of driver gene variation in early stage non-small cell lung cancer

Fluorescence quantitative polymerase chain reaction (PCR) was used to detect the variation of driver gene in regional lymph nodes of early stage non-small cell lung cancer (NSCLC), and to analyze the relationship between the variation and disease recurrence and survival prognosis. evaluate the effect of the variation of driving gene in lymph nodes of early stage NSCLC on prognosis, identify the high-risk factors that promote the recurrence and metastasis of early stage tumor. so as to improve the diagnosis and treatment path of lung cancer, provide important pathological basis for the clinical diagnosis and treatment of early stage non-small cell lung cancer, enable patients to receive more accurate treatment, and improve their survival prognosis.

Eligibility Criteria:
Inclusion Criteria:

1. Female or male, 18 years of age or older
2. Histologically or cytologically proven diagnosis of early stage NSCLC
3. The lesion was completely resected by radical surgery
4. Able to get tumor tissue sample
5. Complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up

Exclusion Criteria:

1. Combine with other tumor type
2. The investigator judges the situation that may affect the clinical search process and results
Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure - Preliminary Study

This study evaluate the effect of dexmedetomidine on intelligence test in pediatric patients with multiple anesthesia exposure. Children who are diagnosed with retinoblastoma and receive first exam under general anesthesia before age of 2 are included. Intelligence test will performed when patients' age are 4.


Eligibility Criteria:
Inclusion Criteria:

* Patients who are first diagnosed as retinoblastoma and scheduled for EUA and treatment under general anesthesia before age of 2

Exclusion Criteria:

-
INSIGHT (R)XT. Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT

To describe the clinical indications for Reveal XT in diagnosis and continuous monitoring of arrhythmia and to explore the clinical applications and outcome of arrhythmia monitoring on patient care.

Improving the diagnosis and management of cardiac rhythm disturbances remains a major challenge for physicians. Limitations of current cardiac arrhythmia monitoring using ECG, holters or event recorders are that these methods are non-continuous and/or automatic arrhythmia detection is often impossible. The Medtronic Reveal XT Insertable Cardiac Monitor is a programmable device which continuously monitors the patient's subcutaneous ECG and provides information regarding arrhythmia episodes, long term trending of AF burden, patient's activity and heart rate variability. The Reveal XT records cardiac information in response to patient activation and automatically detected arrhythmias thereby offering advantages over conventional tools for long-term arrhythmia monitoring with regard to compliance and recording time.

The clinical applications for Reveal XT are varied. Diagnostic, arrhythmia monitoring and arrhythmia management functions can be discriminated.

This study is a prospective, observational, multicenter international post-market study. The results of this study will describe the different patient groups for which the Reveal XT is being used for the diagnosis and monitoring of various cardiac arrhythmias. This study will also collect data regarding the clinical consequences of using the Reveal XT and the influence of Reveal XT data on clinical care pathways. The physician as well as the patient's satisfaction with the device will be evaluated. The study will be conducted in 60-100 centers primarily in Europe. It is expected that 800-1000 patients will be enrolled.

Eligibility Criteria:
Inclusion Criteria:

* Patient implanted or scheduled for an implant with a Reveal XT Insertable Cardiac Monitor System for arrhythmia diagnosis or monitoring
* Patient must be willing to sign a Patient Data Release Form (or Informed Consent where applicable)

Exclusion Criteria:

* Enrollment outside a 30-day window from the planned/performed Reveal XT implant procedure (from 15 days pre-implant until 15 days post implant)
* Patient is implanted with a pacemaker, ICD, CRT-device or an implantable hemodynamic monitoring system
* Unwillingness or inability to cooperate or give written informed consent or, if the patient is a minor and the legal guardian refuses to give consent
Assessment of Autonomic Nervous Regulation During Postnatal Period in Newborns

The project aims to assess the regulatory mechanisms of autonomic nervous system using noninvasive methods in newborns during postnatal adaptation period. Evaluated parameters will include complex analysis of electrodermal activity as a parameter reflecting sympathetic cholinergic system and indices of heart rate variability reflecting the activity of parasympathetic cardiac regulation. The project is focused on the neuro-psycho-physiological characteristics of physiological adaptation in early postnatal age and the effect of non-pharmacological pain relieving.


Eligibility Criteria:
Inclusion Criteria:

* healthy term newborns
* physiological postnatal adaptation
* signed parental informed consent

Exclusion Criteria:

* preterm delivery
* impaired postnatal adaptation
* perinatal infection
* congenital diseases and genetic anomalies
* hypoglycemia
* hyperbilirubinemia requiring phototherapy treatment
Dalfampridine for Imbalance in Multiple Sclerosis

Dalfampridine is a new medication that was FDA approved in 2010 to improve walking speed in people with Multiple Sclerosis (MS). People with MS walk slowly in part because MS damages the myelin insulation around nerves which slows conduction of messages from the brain to the leg muscles. Dalfampridine works by improving conduction in nerves with damaged myelin. Recent research indicates that imbalance in MS is in large part caused by poor conduction by the nerves that transmit information about the position of the legs to the brain. It is therefore likely that, by improving nerve conduction, dalfampridine will also improve imbalance in people with MS. Dalfampridine will be administered in this study by the same route (oral), dosage (10mg), and frequency (every 12 hours) approved by the FDA to improve walking speed in people with MS. The proposed pilot study will examine the effects of dalfampridine on imbalance in 24 subjects with Multiple Sclerosis (MS) and imbalance. This small pilot study will help to show if dalfampridine improves imbalance in MS and will guide the design and implementation of a larger full scale study to definitively determine if dalfampridine improves balance and prevents falls in people with MS.


Eligibility Criteria:
Inclusion Criteria:

* Age 20- 59 years,
* Able to walk at least 100m without an aide or with unilateral assistance
* Prolonged APR latencies (≥ 1SD \> mean for healthy people in this age range) OR,
* Reduced balance-related activity (ABC scores ≤ 85%),
* Abnormal trunk range of motion (horizontal), trunk range of motion (frontal), turning duration, cadence, double support time, stride length or gait cycle time (outside 1SD of the average for healthy people in this age range)

Exclusion Criteria:

* Currently taking dalfampridine (any within the last 2 weeks),
* Cause(s) of imbalance other than MS,
* Impaired renal function (creatinine clearance ≤50mL/min),
* Seizure disorder
* Pregnancy or breast feeding
MCG Discovery Study in Emergency Departments

This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question it aims to answer is whether interpretable data can be reliably collected as part of an ED workflow.


Eligibility Criteria:
Inclusion Criteria:

* Presents to ED with symptoms of Acute Coronary Syndrome (ACS)
* Can provide written consent

Exclusion Criteria:

* Presents to ED with ST-Elevation Myocardial Infarction (STEMI)
* Presents to ED with Atrial Fibrillation
* Clear non-ischemic cause for symptoms (i.e. trauma)
* Active thoracic metal implants
TARGet Kids!: Measuring Nutrition in Young Preschool Children in the Primary Care Practice Setting

TARGet Kids! (The Applied Research Group for Kids) is a research study enrolling healthy children aged 0-5 years. The aim of the TARGet Kids! registry is to link early life exposures to health problems including obesity, micronutrient deficiencies, and developmental problems.

TARGet Kids! represents an innovative collaboration between child health researchers and children's primary care doctors (pediatricians and family physicians) to promote research that really matters and create solutions to some of the today's biggest health concerns. The results of this collaborative research study are not only improving the quality of children's healthcare but also the health of children across the country. Coordinated by Sick Kids and St. Michael's Hospital with data management services by the Applied Health Research Centre (AHRC), TARGet Kids! is the only primary care research network for children in Canada.


Eligibility Criteria:
Inclusion Criteria:

* Birth to less than 6 years of age
* Parental consent
* Attending a TARGet Kids! research network practice

Exclusion Criteria:

* Chronic illness with the exception of asthma
A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours

This is a study using an autocontrol approach, enrolling 40 patients with tumours of epithelial origin, who underwent 68Ga- MY6349 and 68Ga-PSMA/18F-FDG PET/CT imaging of patients with tumours of epithelial origin to compare the ability to diagnose, stage and monitor recurrence of tumours of epithelial origin using the pathological findings as the gold standard.


Eligibility Criteria:
Inclusion Criteria:

- Age ≥ 18 years; Patients with pathologically confirmed tumour and proposed surgical resection/exploration (including primary or recurrent metastatic tumour); Expected survival \> 3 months, as judged by the doctor; Voluntarily sign the informed consent form; willing and able to follow the study protocol

Exclusion Criteria:

- Persons with a known history of hypersensitivity to 68Ga-MY6349 and 68Ga-PSMA or 18F-FDG and their excipients; Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); Patients who have received anti-tumour therapy before the examination or neoadjuvant chemotherapy/targeted therapy for tumour reduction after the examination and up to the preoperative period; Pregnant and lactating women; Practitioners who need to be exposed to radioactive conditions for a long time; Serious diseases of heart, kidney, lung, vascular, neurological and psychiatric systems, immunodeficiency diseases and hepatitis/cirrhosis; Have participated in other interventional clinical trials within 1 month prior to screening; Patients undergoing chemotherapy, immunotherapy or molecular targeted therapy; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.